49 results about "Nicergoline" patented technology

The invention discloses a nicergoline pill and a preparation method thereof. Preparation comprises nicergoline, diluent, disintegrant, adhesive, lubricant and film coating premixing agent. The preparation method includes uniformly mixing the diluent with the internally added disintegrant; preparing blank particles in proper quantity by the adhesive, drying, pelleting and reserving; independently pelleting main drug by the proper adhesive, quickly drying, pelleting and reserving at lower temperature; uniformly mixing the main drug particles with the blank particles, adding externally added auxiliaries, mixing totally, pressing, coating a thin film and packaging. Accordingly, flowability of the particles is guaranteed, the drug can be dissolved beneficially, and more importantly, the problems that content of the main drug and the auxiliaries is lowered and relevant substances are increased due to the high drying temperature and long time in pelleting are avoided. Compared with the prior art, the nicergoline pill has the advantages of reasonable components, simplicity in process, unique preparation method, high dissolving degree, good stability of the preparation, low cost and the like.

The invention discloses a novel synthesis method for the raw material medicine of nicergoline (shown in formula I). The novel synthesis method disclosed by the invention comprises the following steps of: reacting ergosterol with 5-bromonicotinate derivatives to generate carboxylic ester; then performing a photocatalytic reaction with methanol in an acidic condition; and then performing a methylation reaction with a methylation reagent to generate nicergoline. With the adoption of the novel synthesis method disclosed by the invention, the cumbersome operation of the methods disclosed by the existing patents is avoided, the used solvent is low in toxicity, and the yield is high. The novel synthesis method is beneficial to industrialized popularization and application.

Compositions, and methods of use thereof, are provided for the prevention, treatment or alleviation of symptoms of hearing are provided. The methods employ nicergoline, MMDL or MDL as the sole active pharmaceutical agent or a combination of nicergoline, MMDL or MDL and another pharmaceutical agent, such as an antioxidant, a NMDA antagonist, an SSRI or a combined SSRI/NMDA antagonist agent. The method involves the use of nicergoline, MMDL or MDL alone or in combination with another API to prevent, treat or ameliorate one or more symptoms of hearing loss.

The invention discloses a preparation method for nicergoline. The preparation method for the nicergoline comprises the following steps: 1) reacting ergot alcohol in a methanol-sulfuric acid system under photocatalysis to prepare 10alpha-methoxyl-light ergot alcohol; 2) performing methylation on the 10alpha-methoxyl-light ergot alcohol and a methylated reagent in an aprotic polar solvent under the catalytic action of strong alkali to prepare 1-methyl-10alpha-methyl-light ergot alcohol; and 3) performing acylation reaction on the1-methyl-10alpha-methyl-light ergot alcohol and 5-bromine nicotinoyl halide in an aprotic hydrophobic solvent under the catalytic action of weak alkali to prepare the nicergoline. The solvents and catalysts adopted by the method have the advantages of low toxicity, low price, simple aftertreament and the like, so that the reaction residues of the products can be reduced, the quality of the product can be improved, and the requirement of environment-friendly production can be met.

The invention discloses a method for producing nicergoline, which takes a multifunctional reaction kettle with a special kettle bottom valve as a reactor, a special filter as refining equipment and lysergol as an original raw material and comprises the following steps: directly carrying out photoreaction at room temperature in sulfuric acid-methanol to obtain 10alpha-methoxy optical lysergol; reacting the 10alpha-methoxy optical lysergol with methyl iodide under an alkaline condition to obtain 1-methyl-10alpha-methoxy optical lysergol; and directly forming ester with 5-bromine niacin to produce the nicergoline. Compared with the method for producing the nicergoline through current synthesis equipment, the disclosed production process of the nicergoline has the advantages of few reaction steps, mild reaction conditions, convenient refinement, simple operation, good effects of heat preservation, oxidation resistance, sealing property and environmental protection of the used special equipment, complete reaction, simple structure of reaction equipment, convenient operation, easy disassembling, assembling and cleaning, high filtering efficiency, high reaction quality and yield, and stable product quality.

The present invention discloses application of bilobalide as a synergist in preparation of a drug or a heath product for preventing cranial nerve injury diseases. An inventor discovers that compounds of bilobalides, particularly bilobalide, bilobalide extracts, and hydroxyl derivatives of bilobalides, particularly glucoside derivatives, ester derivatives and ether derivatives can well promote drug molecules with a treating or health care function on cranial nerve injury diseases to enter brain tissues, wherein the drug molecules comprise ginsenoside, stibene glucoside, resveratrol, levodopa, edaravone, vinpocetine, nicergoline, citicoline, oxiracetam and the like; under the conditions of not increasing drug concentration in blood, the concentration of bilobalide can be increased to a large extent in the brain tissues, so that the efficacy of the drug can be improved, and side effects and adverse reactions of the drug can be reduced.

The invention discloses a mini-pill type nicergoline capsule and a preparation method thereof. The mini-pill type nicergoline capsule is a sustained-release preparation and is prepared from a capsule shell and a nicergoline mini-pill accommodated in the capsule shell, wherein the nicergoline mini-pill sequentially comprises an empty pill core, a main drug layer and a pigmented layer from inside to outside; the main drug layer accounts for 15-60 percent of the empty pill core, and the pigmented layer accounts for 0.5-1 percent of the total weight of the empty pill core and the main drug layer. The mini-pill type nicergoline capsule has the advantages of small stimulation to intestines and stomach, high utilization rate, high stability, less toxic or side effects and capability of fully releasing effective components in time.

The invention belongs to the field of medicine analysis, and particularly relates to a high performance liquid chromatography method for determining nicergoline related substances. According to the high performance liquid chromatography method, a filler obtained by mixing strong cation exchange resin and a reversed phase C18 according to a volume ratio of 1 to 4 is used as a filling agent, acetonitrile is used as a mobile phase A, a phosphate buffer is used as a mobile phase B, the mobile phase A and the mobile phase B are mixed according to a ratio of 30 to 70 for isocratic elution, the detection wavelength is 288nm, and the column temperature is 30 DEG C. By the high performance liquid chromatography method, the content of an impurity D can be accurately determined and known impurities C, B, A, G, F and H and other unknown impurities in nicergoline can be simultaneously determined.

The invention relates to a new preparation method of nicergoline. The method comprises the following steps: (1) adding an inorganic alkali into a polar aprotic solvent, and carrying out a methylationreaction on lysergol (II) and a methylation reagent to generate 1-methyl lysergol (III); (2) carrying out a light reaction on the 1-methyl lysergol (III) and methanol under the catalysis of concentrated sulfuric acid to prepare 1-methyl-10 alpha-methoxy dihydrolysergol (IV); and (3) in a polar aprotic organic solvent, carrying out a reaction on 5-bromonicotinic acid (V) and N,N'-carbonyl diimidazole by taking the N,N'-carbonyl diimidazole as a condensing agent to prepare a 5-bromo nicotinyl imidazole (VI) intermediate, and then carrying out a condensation reaction on the 5-bromo nicotinyl imidazole (VI) intermediate and the 1-methyl-10 alpha-methoxy dihydrolysergol (IV) to prepare nicergoline (I). Compared with the method in the prior art, the method of the invention does not require inertgas protection, is small in acid consumption, good in product quality, high in yield, easy in reaction byproduct recovery and utilization and suitable for industrial production.

An oral disintegrating tablet of nicergoline contains nicergoline and auxiliaries including sorbitol, methylacryl copolymer resin (Eudragit L30D), citric acid, sodium dicarbonate, magnesium stearate, SiO2 and lemon perfume.

The invention relates to a preparation method of a rapidly disintegrated nicergoline tablet. The method comprises a necessary key step: that is, microcrystalline cellulose-sodium carboxymethylcellulose granules are first prepared by a wet granulation method and then mixed with other auxiliary materials, so that the prepared nicergoline tablet can be rapidly disintegrated by the granules. The tableting process provided by the invention is a powder direct compression process: the prepared microcrystalline cellulose-sodium carboxymethylcellulose granules, nicergoline, dibasic calcium phosphate and magnesium stearate are directly mixed; and then tabletting, coating and aluminum-plastic packaging are executed to obtain a finished product. Each inspection index of the nicergoline tablet preparedby the method is qualified, the disintegration time is less than or equal to 2 minutes, and the nicergoline tablet can rapidly and completely disintegrate in an inspected dissolution medium to realize rapid dissolution. A disintegrating agent easily absorbing moisture is not used in the prescription, and the prepared nicergoline tablet has excellent stability. The preparation method of the nicergoline tablets p is novel in method and simple in process, and well solves the problems of no disintegration and poor stability of the existing marketed nicergoline tablets.

The invention provides an injection used nicergoline freeze-dried powder injection which is prepared by freeze-drying a nicergoline medicine solution with the pH value being 3.2-3.5. Every 2000 ml ofthe nicergoline medicine solution contains 80-120 g of nicergoline, 12-18 g of mannitol, 18-22 g of acetylcysteine, 2-3 g of monopotassium phosphate, 3-5 g of Tween 80, a proper amount of a pH regulating agent, and the balance of water. In the formula of the nicergoline freeze-dried powder injection, the proper amounts of ingredients, such as mannitol, acetylcysteine, Tween 80 and monopotassium phosphate, are added, all components play a synergistic effect, the appearance shape and porosity of the freeze-dried product can be improved, and the surface of the product is smoother; meanwhile, medicine properties are more stable, and storage and transportation of the medicine are facilitated.

The invention relates to a drug compound playing the role of retarding Alpha-receptors and expanding blood vessels, and is used for improving low desires and affective disorders due to cerebral arteriosclerosis and stroke sequelae and treating vascular dementia. The drug compound aims to supplement the deficiency of the prior oral pharmaceutical formulation used for hemangiectasis and provide a drug compound oral formulation, sustained-release nicergoline dropping pill which has high bioavailability, steady plasma concentration, low frequency of drug taking, low cost and absence of contamination during the production. The sustained-release nicergoline dropping pill adopts nicergoline as the ingredient and is prepared jointly with the medicinal carrier used as the stroma.

The invention discloses a serum-free culture medium of CAR-T cells. The serum-free culture medium consists of a basic culture medium and the following components added into the culture medium: nicergoline, icariin, ferulate, IL-2, IL-15, vitamin E and L-glutamine. The nicergoline and the icariin are added into the serum-free culture medium of the CAR-T cells in the invention, so that the proliferation activity of the CAR-T cells can be effectively improved; and a large number of CAR-T cells can be harvested within a short time. The ferulate is also added, so that the number of living cells in the harvested cells is easily increased; and the cell survival rate is increased. The components, the L-2, the IL-15, the vitamin E and the L-glutamine jointly act; the proliferation activity of the CAR-T cells is improved; the used components are safe; blood components such as plasma are not added; the culture cost of the CAR-T cells is reduced; and the burden of a patient is relieved. The invention further provides a culture method of the CAR-T cells; the culture method is simple and convenient to operate and easy to implement; and popularization and application of the CAR-T cells in the field of tumour immunotherapy are facilitated.

The invention relates to the technical field of medicine, in particular to a preparation method of a nicergoline tablet. The nicergoline tablet is sequentially provided with a pill, a second main medicine layer, a coating inner layer, a first main medicine layer and a coating outer layer from inside to outside; and the thickness ratio of the second main medicine layer to the coating inner layer tothe first main medicine layer to the coating outer layer is (1-2):(4-5):(1-2):(1-2). a tablet inner layer is arranged, so that the medicine can be disintegrated hierarchically, the action time of themedicine is prolonged, and absorption is facilitated; and the nicergoline is uniformly dispersed in phospholipid, so that the affinity between the nicergoline and grease is increased, the dissolutionrate of the nicergoline is further increased, and the utilization rate is increased. By arranging a hollow tablet shell, the dissolution time of the tablet shell is shortened, the medicine is exposedas soon as possible to play a role, and a patient is treated with the medicine early; in addition, the tablet shell contains gelatin and corn starch, so that the tablet shell is softened and decomposed when meeting water and can be absorbed by the human body, and the dissolution time of the tablet shell is also shortened;.

A nicergoline lipid microspheres agent is mainly prepared by nicergoline, oil for injection, an emulsifying agent and an isotonic agent. The nicergoline lipid microspheres agent has a perfect curative effect, the problems that the nicergoline cannot be dissolved in water and unwelcome reactions can be produced when the dosage of the nicergoline is large are solved, the medicine stability is improved, irritation and toxic reaction are reduced, the quality of the nicergoline lipid microspheres agent is improved, and the nicergoline lipid microspheres agent is suitable to be industrially produced widely.

The invention provides a nicergoline lyophilized preparation with excellent stability. The nicergoline lyophilized preparation is prepared by freeze-drying a nicergoline drug solution, and each 1000 gof the nicergoline drug solution comprises: 2-4 g of nicergoline, 0.5-1 g of tartaric acid, 0.2-9 g of sodium chloride, 20-40 g of an excipient, and an appropriate amount of water for injection, andthe pH value of the drug solution is 3.0-5.0. In the formula of the lyophilized preparation, mannitol is used to replacing lactose in an original development agent to be a lyophilized excipient, which can avoid the risks of allergies, pyrogens, and mad cow disease caused by lactose as an injection adjuvant, and overcomes the instability caused by the absence of lactose in the prior art. The mostnotable feature of the preparation is the combination of mannitol, sorbitol and the like with sodium chloride, and the nicergoline for injection still has excellent stability without using of nicergoline. The lyophilized product of the invention has rapid reconstitution and loose appearance, and is convenient for transportation and preservation and clinical use.

The invention relates to the technical field of preparation of medicines for treating tumors, in particular to application of nicergoline and derivatives thereof in preparation of medicines for treating tumors. The nicergoline is used as a medicine for treating tumors and can be used for effectively treating tumors, especially lung squamous cell carcinoma, so that the lifetime of tumor patients, especially lung squamous cell carcinoma patients, is prolonged.